| 1 |
27562051 | [Impact of olmesartan medoxomil on atherosclerosis lesions in apolipoprotein E knockout mice]. | 2016 Aug 16 |
1 |
| 2 |
26251572 | Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis. | 2015 |
1 |
| 3 |
23177972 | Angiotensin II promotes aortic valve thickening independent of elevated blood pressure in apolipoprotein-E deficient mice. | 2013 Jan |
1 |
| 4 |
23124103 | Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice. | 2012 Dec |
3 |
| 5 |
20399087 | Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production. | 2011 Sep |
1 |
| 6 |
21464389 | Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. | 2011 May |
2 |
| 7 |
20079903 | AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice. | 2010 Jun |
2 |
| 8 |
18344628 | Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. | 2007 Dec |
1 |